Literature DB >> 3485248

Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency.

S Eriksson, J Carlson, R Velez.   

Abstract

Previous reports have suggested an association between homozygous alpha 1-antitrypsin deficiency, cirrhosis, and primary liver cancer. To assess the risk of these complications we conducted a retrospective study based on 17 autopsied cases of alpha 1-antitrypsin deficiency identified during the period 1963 to 1982 in the city of Malmö, Sweden. During the study period, autopsies were performed in 38,250, or 68.2 percent, of all patients in the city who died. From the homozygote frequency in the population, 21 of these were expected to have alpha 1-antitrypsin deficiency. The disease had been diagnosed in 20, and autopsies had been performed in 17 (1 child and 16 adults). Each autopsied case was matched with four controls selected from the same autopsy register, and the Mantel-Haenszel odds ratio (ORmh) was calculated. The results indicated a strong relation between alpha 1-antitrypsin deficiency and cirrhosis (ORmh = 7.8; 95 percent confidence limits, 2.4 to 24.7) and primary liver cancer (ORmh = 20; 95 percent confidence limits, 3.5 to 114.3). When data were stratified according to sex, these associations were statistically significant only for male patients. We conclude that men with alpha 1-antitrypsin deficiency may be at higher risk for cirrhosis and primary liver cancer. The apparent male predominance suggests the additive effects of exogenous factors.

Entities:  

Mesh:

Year:  1986        PMID: 3485248     DOI: 10.1056/NEJM198603203141202

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  133 in total

Review 1.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 2.  Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury.

Authors:  David H Perlmutter
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  A novel model and molecular therapy for Z alpha-1 antitrypsin deficiency.

Authors:  Gillian L McNab; Timothy R Dafforn; Alice Wood; Elizabeth Sapey; Robert A Stockley
Journal:  Mamm Genome       Date:  2011-11-11       Impact factor: 2.957

4.  Alpha(1)-Antitrypsin Deficiency.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-12

Review 5.  Genetic predisposition to alcoholic liver disease.

Authors:  C P Day; M F Bassendine
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

Review 6.  Novel treatment strategies for liver disease due to α1-antitrypsin deficiency.

Authors:  Nicholas Maurice; David H Perlmutter
Journal:  Clin Transl Sci       Date:  2012-01-10       Impact factor: 4.689

Review 7.  Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far?

Authors:  Marion Bouchecareilh
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

8.  Multiple tissues express alpha 1-antitrypsin in transgenic mice and man.

Authors:  J A Carlson; B B Rogers; R N Sifers; H K Hawkins; M J Finegold; S L Woo
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

9.  Diagnosis of alpha 1-antitrypsin deficiency by enzymatic amplification of human genomic DNA and direct sequencing of polymerase chain reaction products.

Authors:  C R Newton; N Kalsheker; A Graham; S Powell; A Gammack; J Riley; A F Markham
Journal:  Nucleic Acids Res       Date:  1988-09-12       Impact factor: 16.971

10.  Synthesis of stress proteins is increased in individuals with homozygous PiZZ alpha 1-antitrypsin deficiency and liver disease.

Authors:  D H Perlmutter; M J Schlesinger; J A Pierce; P I Punsal; A L Schwartz
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.